Founded with a mission to innovate in the biopharmaceutical sector, CiVi Biopharma is a clinical-stage biotechnology company based in the United States. The company focuses on research and development of novel oral antisense oligonucleotide therapies targeting cardiovascular and metabolic diseases. By leveraging cutting-edge science, CiVi Biopharma aims to address significant unmet medical needs in these critical areas.
CiVi Biopharma's leadership includes experienced professionals from the biotech and pharmaceutical industries, contributing to its strategic direction and scientific advancements. The company has garnered attention for its promising pipeline, including key projects like CiVi 030 and CiVi 008. Through its innovative approach and dedicated R&D efforts, CiVi Biopharma is making a substantial impact on the treatment landscape for cardiovascular and metabolic conditions.
